Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-6.49 Insider Own2.30% Shs Outstand349.87M Perf Week-12.32%
Market Cap5.03B Forward P/E2.99 EPS next Y4.81 Insider Trans-30.14% Shs Float332.27M Perf Month6.76%
Income-2256.30M PEG- EPS next Q1.21 Inst Own66.80% Short Float10.72% Perf Quarter-15.41%
Sales10.01B P/S0.50 EPS this Y-133.00% Inst Trans20.06% Short Ratio2.33 Perf Half Y-53.36%
Book/sh11.92 P/B1.21 EPS next Y-11.59% ROA-4.70% Target Price22.39 Perf Year-78.15%
Cash/sh1.88 P/C7.64 EPS next 5Y9.00% ROE-42.90% 52W Range13.00 - 76.95 Perf YTD-0.96%
Dividend- P/FCF12.96 EPS past 5Y4.40% ROI3.70% 52W High-81.80% Beta-0.12
Dividend %- Quick Ratio1.10 Sales past 5Y54.60% Gross Margin73.80% 52W Low7.73% ATR0.77
Employees22000 Current Ratio1.50 Sales Q/Q-11.00% Oper. Margin-5.20% RSI (14)41.30 Volatility6.42% 4.79%
OptionableYes Debt/Eq7.31 EPS Q/Q- Profit Margin-22.50% Rel Volume1.47 Prev Close14.38
ShortableYes LT Debt/Eq7.29 EarningsFeb 28 BMO Payout- Avg Volume15.28M Price14.01
Recom3.00 SMA20-8.52% SMA50-5.97% SMA200-34.02% Volume17,917,240 Change-2.61%
Feb-27-17Reiterated Mizuho Underperform $11 → $9
Feb-14-17Reiterated RBC Capital Mkts Sector Perform $29 → $22
Feb-10-17Reiterated Barclays Equal Weight $34 → $20
Jan-04-17Reiterated Piper Jaffray Underweight $16 → $11
Dec-15-16Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $17
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Nov-10-16Downgrade Rodman & Renshaw Buy → Neutral $81 → $23
Nov-09-16Reiterated RBC Capital Mkts Sector Perform $35 → $29
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Aug-10-16Reiterated RBC Capital Mkts Sector Perform $31 → $36
Aug-10-16Reiterated Piper Jaffray Underweight $19 → $22
Aug-09-16Reiterated Rodman & Renshaw Buy $90 → $81
Jun-23-16Downgrade JP Morgan Overweight → Neutral
Jun-08-16Reiterated Stifel Buy $65 → $55
Mar-01-17 11:14AM  Valeant: The Long and Winding Road at Barrons.com
10:10AM  Company News for March 01, 2017
08:21AM  5 Things Valeant's Management Said That You Probably Wish It Hadn't at Motley Fool
01:06AM  [$$] Valeants Revenue Falls 13% at The Wall Street Journal
Feb-28-17 07:04PM  [$$] Valeant's Revenue Falls 13% at The Wall Street Journal -13.94%
05:38PM  Valeant updates status of Bausch & Lomb Tampa plant at bizjournals.com
04:42PM  Valeant will relaunch female Viagra drug with poor track record at MarketWatch
04:13PM  Kite, Ionis Outplay Med Sector As Perrigo, Tenet, Valeant Dive
04:13PM  Valeant Gets Rocked as Investors Weigh Ability to Drive Organic Growth
04:00PM  Valeant Plunges On 2017 Earnings Outlook, 'Unrealistic' Brand Sales
02:59PM  Stocks Drop as Markets Grow Impatient Ahead of Trump's Congressional Address
02:42PM  Why Valeant Pharmaceuticals Is Tumbling Today at Motley Fool
01:58PM  Valeant's Leverage Could Reach '8x or Worse' Says Gimme Credit at Barrons.com
01:04PM  Valeant: 'Saying It Does Not Make It So' at Barrons.com
12:30PM  "New Valeant" Looks Suspiciously Like the Old One
12:27PM  Valeant: Just When Things Were Looking Up For Ackman at Barrons.com
12:05PM  Why Valeant Missed the Mark Despite an Earnings Beat
12:02PM  Valeant Pharmaceuticals Is a Potential Sell
11:24AM  Big Money Still Long Valeant
10:39AM  Bill Ackman's nightmare stock can do no right
10:27AM  Valeant Pharmaceuticals Reports Steeper Q4 Loss on Lower Product Sales at Motley Fool
10:18AM  Valeant Meltdown After Bad Q4 & FY16 Earnings at Investopedia
10:11AM  Valeant predicts tough 2017 with revenue to decline
10:05AM  Why Valeant's Earnings Beat Doesn't Matter at Barrons.com
09:40AM  Stocks Open Lower; Priceline, Nutrisystem Jump; Target Plunges
09:36AM  Target sinks to multi-year low, Priceline pops to new high, Valeant falls despite beat
09:25AM  Stocks to Watch: Target, Valeant Pharma, Domino's at The Wall Street Journal
08:50AM  Morning News Call Canadienne - Février 28
08:34AM  Is the Options Market Predicting a Spike in Valeant Pharmaceuticals International (VRX) Stock?
08:20AM  Investors prepare for Trump in prime time as Fidelity cuts commissions, YouTube passes 1B hours of daily viewing
08:19AM  Valeant reports 4Q loss
07:40AM  Stock Futures Little Changed as Trump Prepares to Lay Out His Policy Plans
07:20AM  Why You Should Wait to Buy These 3 Stocks at Motley Fool
07:19AM  Valeant posts wider loss for fourth quarter as revenue dips at MarketWatch
07:18AM  Valeant's Declining Sales Show Turnaround Has Long Way to Go
07:11AM  Valeant Pharma's revenue falls for third straight quarter
07:03AM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financ
07:00AM  Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance PR Newswire
07:00AM  Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance CNW Group
Feb-27-17 05:05PM  The Only Number That Matters When Valeant Pharmaceuticals Reports Its Q4 Results at Motley Fool
04:26PM  A quick reminder that Bill Ackman's worst nightmare is still very much a thing
03:29PM  5 Stocks to Watch Before the Market Opens Tomorrow
01:32PM  Why Valeant Might Beat Earnings Expectationsand Why It Won't Matter at Barrons.com
01:23PM  Jim Cramer Is Passing on Valeant Ahead of Earnings
01:14PM  5 Earnings Short-Squeeze Plays to Boost Your Returns
11:07AM  Valeant Ups Sales Force Ahead of Q4 Results at Investopedia
10:19AM  Valeant Pharmaceuticals Stock Climbs Ahead of Earnings Release
10:05AM  Why Valeant is Flying on the Eve of Earnings at Barrons.com
09:12AM  Valeant's High Debt Load Puts Q4 Focus On EBITDA Guidance
08:00AM  Valeant Pharmaceuticals: Overvaluation Situation at Investopedia
07:13AM  Valeant sub Salix hired 250 employees to bolster its GI commitment at MarketWatch
07:00AM  Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity PR Newswire
07:00AM  Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity CNW Group
01:51AM  Facing Criticism, Drug Makers Keep Lid On Price Increases at The Wall Street Journal
01:30AM  Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod PR Newswire
01:30AM  Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod CNW Group
Feb-26-17 08:03PM  Drug Companies Keep Lid on Price Increases at The Wall Street Journal
Feb-25-17 10:25AM  Top Biopharma Movers of the Past Week
Feb-24-17 01:29PM  Sequoia Fund wins dismissal of lawsuit over huge Valeant stake
10:47AM  Valeant's Ugly Earnings History May Repeat Itself at Barrons.com
07:58AM  The Demise Of The Erectile Dysfunction TV Ads at Forbes
Feb-23-17 11:43AM  Former Valeant and Philidor executives plead not guilty in fraud scheme Reuters
11:28AM  Former Valeant and Philidor execs plead not guilty in fraud scheme Reuters
11:07AM  Did 50 Salespeople Leave Valeant? Wells Fargo Investigates at Barrons.com
07:00AM  Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products PR Newswire
07:00AM  Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products CNW Group
02:08AM  PRESS DIGEST- New York Times business news - Feb 23 Reuters
Feb-21-17 05:25PM  Tiny Waltham biotech's market cap doubles after $103M Valeant licensing deal at bizjournals.com
03:57PM  Valeant Acquires Eyegate Licensing Rights
11:10AM  Tuesdays Top Biopharma Movers
09:30AM  The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson
07:44AM  EyeGate Pharma surges 15% on news of Valeant licensing agreement at MarketWatch
07:44AM  EyeGate Pharma surges 15% on news of Valeant licensing agreement
07:30AM  Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients PR Newswire
07:30AM  Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients CNW Group
Feb-20-17 03:40PM  This Guru Loves Valeant; Should You?
01:33PM  [$$] Unilever was a deal too far for Kraft Heinz at Financial Times
Feb-19-17 06:00AM  Sequoia's Foundation Looks Stronger Than It Was Before at Morningstar
Feb-17-17 09:12AM  Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.
09:09AM  It Happened Again! Another Drugmaker Got Caught With an Exorbitant Price Hike at Motley Fool
08:05AM  AstraZeneca Stock Rises On Successful Breast Cancer Drug Trial
Feb-16-17 04:41PM  Don't Count on Valeant's New Drug to Save the Day at Motley Fool
01:55PM  Francis Chou Adds to Valeant, Trims Sears in 4th Quarter
01:43PM  Billionaire Bill Ackmans Pershing Square Boosts Bet on Fast Food Industry, Cuts Down on Healthcare at Insider Monkey
12:05PM  Why This FDA Approval for Valeant Is Not as Good as First Thought
11:54AM  New Valeant Approval is a Surprise Irritant at The Wall Street Journal
10:38AM  Valeant Pharmaceuticals: Dead in the Water? at Barrons.com
10:04AM  Stocks to Watch: Kate Spade, MGM Resorts, Avon Products at The Wall Street Journal
09:03AM  Morning Movers: Valeant Jumps, Kate Spade Soars, MGM Drops at Barrons.com
07:22AM  Valeant stock surges 3% after psoriasis drug gets FDA approval at MarketWatch
07:00AM  Valeant Receives FDA Approval Of SILIQ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis PR Newswire
07:00AM  Valeant Receives FDA Approval Of SILIQ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis CNW Group
Feb-15-17 06:37PM  Bill Ackman Expands Chipotle Position, Cuts Zoetis +5.51%
06:34PM  FDA approves Valeant's drug to treat plaque psoriasis Reuters
10:49AM  These 3 Hedge Funds Are Playing With Fire at Motley Fool
10:42AM  Eli Lilly Is Great Stock to Buy Now
Feb-14-17 05:24PM  Ackman boosted Chipotle holdings, pared Valeant in 4th quarter at MarketWatch +6.75%
10:39AM  Valeant: Why $3.75 Billion is the Most Important Number at Barrons.com
09:24AM  Valeant, Pershing Square to Split Legal Fees on Allergan Lawsuit
Feb-13-17 05:00PM  Valeant Pharmaceuticals To Participate At Healthcare Conferences PR Newswire
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails. It also provides Nitropress for the immediate reduction of blood pressure of patients in hypertensive crises; Isuprel for heart related treatments; Xenazine for chorea; Uceris to get ulcerative colitis under control; Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; Biotrue for healthy contact lens wear; and ReNu Multiplus to lubricate and rewet soft contact lenses. In addition, the company offers Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; various ophthalmic surgical products; SofLens daily disposable contact lenses; Biotrue ONEday lens; Bausch + Lomb Ultra, a contact lens PureVision, a contact lens; and medical device systems for aesthetic applications. Further, it provides Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Metronidazole to treat bacterial infections; and Latanoprost for the treatment of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September, 2010. The company was founded in 1983 and is based in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ross Thomas W. Sr.DirectorDec 14Buy14.735,00073,65026,822Dec 16 04:19 PM
Pershing Square Capital ManageDirectorDec 12Sale14.853,476,69051,628,84718,114,432Dec 13 04:14 PM
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM
Ross Thomas W. Sr.DirectorJun 13Buy24.404,00097,60021,882Jun 27 03:40 PM
PAPA JOSEPH CCHAIRMAN & CEOJun 10Buy24.48202,0004,944,9602,442,199Jun 13 06:47 AM